^
Association details:
Biomarker:CLDN6 expression
Cancer:Endometrial Cancer
Drug:CTIM-76 (CD3 agonist, CLDN6 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

1872 / 11 - A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models

Published date:
03/15/2023
Excerpt:
Here we introduce CTIM-76, a CLDN6 T-cell engager antibody as a potential treatment of ovarian, endometrial, and other solid tumors....CTIM-76 shows a combination of potent killing of CLDN6-expressing cells, no killing of cells expressing other closely related claudin family members, and excellent productivity and developability….The exquisite specificity of CTIM-76 suggests the potential to address the need for potent therapeutic modalities for ovarian and other cancers without compromising patient safety.